Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729847 | 0.93 | IL2 (1.00) | IL2 | |
| SCHEMBL2729175 | 0.91 | IL2 (0.86) | IL2 | |
| SCHEMBL2727623 | 0.90 | IL2 (0.86) | IL2 | |
| SCHEMBL15216510 | 0.90 | IL2 (0.93) | IL2 | |
| SCHEMBL2728263 | 0.89 | IL2 (0.84) | IL2 | |
| SCHEMBL2729224 | 0.89 | IL2 (0.82) | IL2 | |
| SCHEMBL2728936 | 0.88 | IL2 (0.78) | IL2 | |
| SCHEMBL2727804 | 0.88 | IL2 (1.00) | IL2 | |
| SCHEMBL2727355 | 0.87 | IL2 (1.00) | IL2 | |
| SCHEMBL2727639 | 0.87 | IL2 (1.00) | IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | claimed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | claimed |
| EP-2632906-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2013-09-04 | — | — | EP | claimed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | claimed |
| WO-2012056478-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2012-05-03 | — | — | WO | claimed |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | RYR2, RYR1, GABRR1 | IL2 2413/4885 |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | RYR2, RYR1, ADRA2C | IL2 3012/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | IL2 2980/4885 |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | IL2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.